383 related articles for article (PubMed ID: 22172722)
1. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Amin EM; Oltean S; Hua J; Gammons MV; Hamdollah-Zadeh M; Welsh GI; Cheung MK; Ni L; Kase S; Rennel ES; Symonds KE; Nowak DG; Royer-Pokora B; Saleem MA; Hagiwara M; Schumacher VA; Harper SJ; Hinton DR; Bates DO; Ladomery MR
Cancer Cell; 2011 Dec; 20(6):768-80. PubMed ID: 22172722
[TBL] [Abstract][Full Text] [Related]
2. Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1.
Wagner KD; El Maï M; Ladomery M; Belali T; Leccia N; Michiels JF; Wagner N
Cells; 2019 Jan; 8(1):. PubMed ID: 30641926
[TBL] [Abstract][Full Text] [Related]
3. WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.
Belali T; Wodi C; Clark B; Cheung MK; Craig TJ; Wheway G; Wagner N; Wagner KD; Roberts S; Porazinski S; Ladomery M
Biochim Biophys Acta Gene Regul Mech; 2020 Dec; 1863(12):194642. PubMed ID: 33017668
[TBL] [Abstract][Full Text] [Related]
4. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.
Mavrou A; Brakspear K; Hamdollah-Zadeh M; Damodaran G; Babaei-Jadidi R; Oxley J; Gillatt DA; Ladomery MR; Harper SJ; Bates DO; Oltean S
Oncogene; 2015 Aug; 34(33):4311-9. PubMed ID: 25381816
[TBL] [Abstract][Full Text] [Related]
5. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.
Gammons MV; Lucas R; Dean R; Coupland SE; Oltean S; Bates DO
Br J Cancer; 2014 Jul; 111(3):477-85. PubMed ID: 25010863
[TBL] [Abstract][Full Text] [Related]
6. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.
Nowak DG; Amin EM; Rennel ES; Hoareau-Aveilla C; Gammons M; Damodoran G; Hagiwara M; Harper SJ; Woolard J; Ladomery MR; Bates DO
J Biol Chem; 2010 Feb; 285(8):5532-40. PubMed ID: 19906640
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.
Manetti M; Guiducci S; Romano E; Ceccarelli C; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
Circ Res; 2011 Jul; 109(3):e14-26. PubMed ID: 21636803
[TBL] [Abstract][Full Text] [Related]
8. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.
Gammons MV; Fedorov O; Ivison D; Du C; Clark T; Hopkins C; Hagiwara M; Dick AD; Cox R; Harper SJ; Hancox JC; Knapp S; Bates DO
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6052-62. PubMed ID: 23887803
[TBL] [Abstract][Full Text] [Related]
9. VEGF transcription and mRNA stability are altered by WT1 not DDS(R384W) expression in LNCaP cells.
Cash J; Korchnak A; Gorman J; Tandon Y; Fraizer G
Oncol Rep; 2007 Jun; 17(6):1413-9. PubMed ID: 17487399
[TBL] [Abstract][Full Text] [Related]
10. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
[TBL] [Abstract][Full Text] [Related]
11. The role of VEGF 165b in pathophysiology.
Peiris-Pagès M
Cell Adh Migr; 2012; 6(6):561-8. PubMed ID: 23076130
[TBL] [Abstract][Full Text] [Related]
12. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.
Natoli TA; Liu J; Eremina V; Hodgens K; Li C; Hamano Y; Mundel P; Kalluri R; Miner JH; Quaggin SE; Kreidberg JA
J Am Soc Nephrol; 2002 Aug; 13(8):2058-67. PubMed ID: 12138137
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.
Gonçalves V; Henriques AF; Pereira JF; Neves Costa A; Moyer MP; Moita LF; Gama-Carvalho M; Matos P; Jordan P
RNA; 2014 Apr; 20(4):474-82. PubMed ID: 24550521
[TBL] [Abstract][Full Text] [Related]
14. The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo.
Merdzhanova G; Gout S; Keramidas M; Edmond V; Coll JL; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2010 Sep; 29(39):5392-403. PubMed ID: 20639906
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Supradit K; Boonsri B; Duangdara J; Thitiphatphuvanon T; Suriyonplengsaeng C; Kangsamaksin T; Janvilisri T; Tohtong R; Yacqub-Usman K; Grabowska AM; Bates DO; Wongprasert K
Toxicol In Vitro; 2022 Aug; 82():105385. PubMed ID: 35568131
[TBL] [Abstract][Full Text] [Related]
16. SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.
Hatcher JM; Wu G; Zeng C; Zhu J; Meng F; Patel S; Wang W; Ficarro SB; Leggett AL; Powell CE; Marto JA; Zhang K; Ki Ngo JC; Fu XD; Zhang T; Gray NS
Cell Chem Biol; 2018 Apr; 25(4):460-470.e6. PubMed ID: 29478907
[TBL] [Abstract][Full Text] [Related]
17. Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease.
Batson J; Toop HD; Redondo C; Babaei-Jadidi R; Chaikuad A; Wearmouth SF; Gibbons B; Allen C; Tallant C; Zhang J; Du C; Hancox JC; Hawtrey T; Da Rocha J; Griffith R; Knapp S; Bates DO; Morris JC
ACS Chem Biol; 2017 Mar; 12(3):825-832. PubMed ID: 28135068
[TBL] [Abstract][Full Text] [Related]
18. A murine model of Denys-Drash syndrome reveals novel transcriptional targets of WT1 in podocytes.
Ratelade J; Arrondel C; Hamard G; Garbay S; Harvey S; Biebuyck N; Schulz H; Hastie N; Pontoglio M; Gubler MC; Antignac C; Heidet L
Hum Mol Genet; 2010 Jan; 19(1):1-15. PubMed ID: 19797313
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1.
Matsuzawa-Watanabe Y; Inoue J; Semba K
Oncogene; 2003 Sep; 22(39):7900-4. PubMed ID: 12970737
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway.
Thorsen K; Mansilla F; Schepeler T; Øster B; Rasmussen MH; Dyrskjøt L; Karni R; Akerman M; Krainer AR; Laurberg S; Andersen CL; Ørntoft TF
Mol Cell Proteomics; 2011 Jan; 10(1):M110.002998. PubMed ID: 20938052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
